

Bringcitam Injection

Brivaracetam (10mg) Injection

Brivaracetam Injection is an anticonvulsant medication used in the treatment of epilepsy. It is primarily indicated for the management of partial-onset seizures in patients who cannot tolerate or do not respond adequately to oral therapy. Brivaracetam works by modulating synaptic vesicle protein 2A (SV2A), a protein involved in neurotransmitter release, thereby stabilizing neuronal activity.

Composition:

- **Brivaracetam (10mg):** An anticonvulsant agent targeting SV2A to reduce seizure activity.
-

Indications:

- **Partial-Onset Seizures:** Used as adjunctive therapy for the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy.
 - **Alternative for Oral Therapy:** Suitable for patients unable to take oral medication due to vomiting, surgery, or other medical conditions.
-

Dosage & Administration:

- **Adults and Adolescents (≥ 16 years):**

 - The usual starting dose is 50mg to 100mg/day, divided into two intravenous doses.
 - The maximum dose should not exceed 200mg/day, depending on

the patient's condition and response.

- **Route of Administration:** Intravenous (IV) injection, administered slowly over 2 to 15 minutes by a qualified healthcare professional.
-

Mechanism of Action:

Brivaracetam selectively binds to the synaptic vesicle protein SV2A, reducing abnormal electrical activity in the brain and decreasing the frequency of seizures.

Contraindications:

- **Hypersensitivity to Brivaracetam or any of its components.**
-

Side Effects:

- **Common:**
 - Drowsiness, dizziness, or fatigue.
 - Nausea or vomiting.
 - Irritability or mood changes.
 - **Serious (rare):**
 - Suicidal thoughts or behaviors.
 - Allergic reactions (e.g., rash, swelling, difficulty breathing).
 - Severe behavioral changes, including aggression or agitation.
-

Precautions:

- **Use with caution in patients with a history of depression, psychiatric disorders, or suicidal ideation.**

- **Adjust dose in patients with renal or hepatic impairment.**
 - **Do not discontinue abruptly; taper dosage under medical supervision to avoid withdrawal seizures.**
 - **Monitor for mood or behavioral changes during treatment.**
 - **Safety and efficacy have not been established in pediatric patients under 16 years.**
-

Drug Interactions:

- **Central Nervous System Depressants: Enhanced sedative effects when used with alcohol or other CNS depressants.**
 - **Carbamazepine/Phenytoin: May require dose adjustments due to altered plasma levels.**
-

Storage:

- **Store in a cool, dry place below 25°C.**
 - **Protect from light and keep the vial tightly sealed.**
 - **Do not freeze.**
-

Note: This medication should only be administered under the supervision of a qualified healthcare provider. Regular monitoring of seizure activity and overall response is essential.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for